Trials / Terminated
TerminatedNCT01803711
Omega 3 FA Supplements as Augmentation in the Treatment of Depression
A Randomized, Double-Blind Placebo-controlled Study Evaluating the Efficacy of Omega 3 Fatty Acid Augmentation of Desvenlafaxine for the Treatment of Major Depressive Disorder in Patients With Medical Illness.
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- UConn Health · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the efficacy of Omega 3 Fatty acid (Omega 3 FA) augmentation of desvenlafaxine (DVS) compared to placebo augmentation of DVS when used to treat depression and anxiety symptoms in patients with select medical conditions (cancer, cardiovascular diseases and diabetes).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Desvenlafaxine | |
| DIETARY_SUPPLEMENT | Omega 3 Fatty acids | |
| DRUG | Placebo (for Omega 3 fatty acid supplement) |
Timeline
- Start date
- 2013-02-01
- Primary completion
- 2016-06-01
- Completion
- 2016-06-01
- First posted
- 2013-03-04
- Last updated
- 2017-12-27
- Results posted
- 2017-12-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01803711. Inclusion in this directory is not an endorsement.